PITPNM3

Across TCGA pan-cancer cohorts, PITPNM3 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated PITPNM3 data layer compared with 22 for mass-spec protein and 6 for mutation status.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher PITPNM3 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated PITPNM3 expression acts as an unfavorable survival marker, although some lineages such as LUAD and GBM show a favorable association.

HNSC, LSCC, and LUAD are the cancer types where PITPNM3 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	DFS	Median	III,IV	0.508	0.814	.027	2	view →
LSCC	DFS	Median	All	0.886	0.969	.035	1	view →
LUAD	OS	Quartile	III,IV	1.000	0.696	.049	1	view →
GBM	DFS	Quartile	All	0.831	0.506	.030	1	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

PITPNM3–HNSC (DFS)

Open the HNSC breakdown →